newsfilter
← Latest News
Business Wire·

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

54% complete response (CR) rate at any time; 43% six‑month CR rate Low rate of progression to muscle-invasive or higher disease (3.2%) Low percentage of patients experienced treatment-related adverse events